What are the drugs for treating heart failure? What is the latest drug for heart failure in China at present?

Simply put, heart failure is the serious terminal stage of various heart diseases, which seriously endangers the health of patients and may even endanger their lives. The treatment of heart failure has also been concerned by people, and its treatment is mainly drugs.

There are several drugs commonly used to treat heart failure: ① diuretics: they can effectively relieve dyspnea and edema in patients with heart failure and improve cardiac function and exercise tolerance; ② Angiotensin Converting Enzyme Inhibitor (ACEI): These drugs are neuroendocrine inhibitors, which can improve left ventricular function, increase left ventricular ejection fraction, relieve symptoms and improve exercise tolerance; ③ Beta blockers: Long-term application can improve cardiac function, increase left ventricular ejection fraction, improve ventricular morphology and delay or reverse myocardial remodeling; ④ Aldosterone receptor antagonist: it has anti-myocardial fibrosis and ventricular remodeling, anti-arrhythmia and diuretic effects; ⑤ Angiotensin Ⅱ receptor antagonist (ARB): Similar to ACEI, if the clinical symptoms are still unsatisfactory after treatment with diuretics, ACEI and β-blockers, and aldosterone receptor antagonist cannot be tolerated, ARB can be added; ⑥ Digitalis drugs: Digoxin is commonly used, which can enhance myocardial contractility and improve blood circulation; ⑦ ivabradine: It can slow down the heart rate and reduce the risk of hospitalization and death; ⑧ TCM treatment: It should be selected according to the actual situation of syndrome development.

At present, the treatment of heart failure in China is also in line with international standards, and new drugs have an indelible effect on the treatment of heart failure. Angiotensin receptor enkephalinase inhibitors (ARNI) is a new drug for the treatment of mental failure.

In 20 17, American Heart Association (ACC)/ American Heart Association (AHA)/ American Heart Failure Association (HFSA) issued an update of the management guidelines for heart failure, which included a new therapy and a new drug-ARNI for patients with heart failure (HFREF) with reduced ejection fraction in phase C. For patients with chronic HFrEF, it is suggested to use RAS inhibitors (ACEI [I, A], ARB [I, A], ARNI [I, B-R]) combined with evidence-based beta blockers and aldosterone receptor antagonists to reduce morbidity and mortality. Patients with cardiac function grade II or III who can tolerate symptoms of ACEI or ARB should use ARNI instead of ACEI or ARB to further reduce morbidity and mortality, but ARNI should not be used at the same time with ACEI, and patients with a history of angioedema should not use ARNI.

We have heard about the great harm of heart failure, and the high-risk groups of heart failure need to be alert to the occurrence of heart failure at all times! If you find symptoms such as chest tightness, shortness of breath, edema and fatigue, you should go to the hospital in time.